MA45625A - Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl - Google Patents
Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axlInfo
- Publication number
- MA45625A MA45625A MA045625A MA45625A MA45625A MA 45625 A MA45625 A MA 45625A MA 045625 A MA045625 A MA 045625A MA 45625 A MA45625 A MA 45625A MA 45625 A MA45625 A MA 45625A
- Authority
- MA
- Morocco
- Prior art keywords
- antibody
- axl
- dosage regimes
- new dosage
- based conjugate
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000611 antibody drug conjugate Substances 0.000 abstract 1
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003442 weekly effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un conjugué anticorps-médicament (adc) basé sur un anticorps se liant à l'axl humain et des compositions pharmaceutiques comprenant l'adc à utiliser dans le traitement d'un cancer, comprenant l'administration à un sujet d'une dose hebdomadaire d'environ 0,45 mg / kg à environ 2,0 mg / kg. Kg d'adc une fois par semaine pendant trois semaines consécutives, suivies d'une période de repos d'une semaine sans aucune administration d'adc, de sorte que la durée de chaque cycle est de 28 jours, période de repos incluse.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2016/066353 WO2017009258A1 (fr) | 2015-07-10 | 2016-07-08 | Conjugués anticorps-médicament spécifiques d'axl pour le traitement du cancer |
US201662410984P | 2016-10-21 | 2016-10-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA45625A true MA45625A (fr) | 2019-05-15 |
Family
ID=60921579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA045625A MA45625A (fr) | 2016-07-08 | 2017-07-07 | Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl |
Country Status (5)
Country | Link |
---|---|
US (1) | US20190233522A1 (fr) |
EP (1) | EP3481868A1 (fr) |
JP (1) | JP2019524713A (fr) |
MA (1) | MA45625A (fr) |
WO (1) | WO2018007592A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
WO2019197506A1 (fr) * | 2018-04-10 | 2019-10-17 | Genmab A/S | Anticorps spécifiques d'axl pour le traitement du cancer |
JP2022502411A (ja) * | 2018-09-26 | 2022-01-11 | ゲンマブ エー/エス | 非小細胞肺がんの処置のためのaxl特異的抗体 |
EP4099989A4 (fr) | 2020-02-06 | 2023-12-13 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Récepteurs de lymphocytes t ciblant des protéines de réparation d'adn défectueux |
US10822379B1 (en) | 2020-03-12 | 2020-11-03 | University of Pittsburgh—of the Commonwealth System of Higher Education | Molecules that bind to SARS-CoV-2 |
EP4230222A1 (fr) | 2022-02-17 | 2023-08-23 | Oxsonics Limited | Polythérapie avec un conjugué anticorps anti-axl-pbd et nanocups |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
EP1973576B1 (fr) | 2005-11-28 | 2019-05-15 | Genmab A/S | Anticorps monovalents recombines et leurs procedes de production |
CN101616671A (zh) * | 2007-01-19 | 2009-12-30 | 卫材R&D管理有限公司 | 胰腺癌治疗用组合物 |
CA2749115C (fr) | 2009-01-09 | 2022-06-21 | Seattle Genetics, Inc. | Regimes posologiques hebdomadaires pour des conjugues anticorps anti-cd30 vc-pab-mmae - medicament |
US20160106861A1 (en) | 2013-04-26 | 2016-04-21 | Spirogen Sarl | Axl antibody-drug conjugate and its use for the treatment of cancer |
BR112015032758A2 (pt) * | 2013-06-28 | 2017-07-25 | Bind Therapeutics Inc | nanopartículas poliméricas de docetaxel para o tratamento de câncer |
JP2017512801A (ja) * | 2014-04-08 | 2017-05-25 | シアトル ジェネティックス, インコーポレイテッド | Cd19抗体薬物コンジュゲートの最適な投薬 |
AU2015286569B2 (en) * | 2014-07-11 | 2021-04-15 | Genmab A/S | Antibodies binding AXL |
EP3229836B1 (fr) * | 2014-12-09 | 2019-11-13 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Anticoprs monoclonaux contre 'axl' |
EP3319993B1 (fr) * | 2015-07-10 | 2020-01-15 | Genmab A/S | Conjugués anticorps-médicament spécifiques d'axl pour le traitement du cancer |
-
2017
- 2017-07-07 JP JP2019500471A patent/JP2019524713A/ja active Pending
- 2017-07-07 US US16/316,000 patent/US20190233522A1/en not_active Abandoned
- 2017-07-07 MA MA045625A patent/MA45625A/fr unknown
- 2017-07-07 EP EP17742194.8A patent/EP3481868A1/fr not_active Withdrawn
- 2017-07-07 WO PCT/EP2017/067101 patent/WO2018007592A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
US20190233522A1 (en) | 2019-08-01 |
EP3481868A1 (fr) | 2019-05-15 |
JP2019524713A (ja) | 2019-09-05 |
WO2018007592A1 (fr) | 2018-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45625A (fr) | Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl | |
RU2404750C2 (ru) | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту | |
WO2017141104A8 (fr) | Procédé d'induction d'une réponse immunitaire prolongée | |
RU2011110765A (ru) | Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения | |
MX2007006707A (es) | Acidos grasos omega-3 y agente dislipidemico para terapia lipidica. | |
RU2014111069A (ru) | Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение | |
JP2015038135A5 (fr) | ||
JP2013231087A5 (fr) | ||
RU2007104774A (ru) | Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы | |
BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
Yavuz et al. | Pharmaceutical approaches to HIV treatment and prevention | |
RU2017120184A (ru) | Лекарства для замедления течения болезни паркинсона | |
JP2019530706A5 (fr) | ||
JP2016505050A5 (fr) | ||
Sunpath et al. | Double-dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South Africa | |
White et al. | Effects of naproxcinod on blood pressure in patients with osteoarthritis | |
MX2017005163A (es) | Composiciones de liberación prolongada de onapristona y métodos. | |
JP2018506533A5 (fr) | ||
US9687518B2 (en) | Medicament for treating muscle and skeletal diseases | |
Patil et al. | Innovative strategies in the diagnosis and treatment of tuberculosis: a patent review (2014–2017) | |
PH12019500516A1 (en) | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof | |
BE1002256A3 (fr) | Medicaments. | |
JP2019529554A5 (fr) | ||
JP2019524782A5 (fr) | ||
HRP20160811T1 (hr) | Upotreba odiparcila u liječenju mukopolisaharidoze |